ClinicalTrials.gg
CompletedNCT00634231Updated Aug 25, 2023

A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors

A Phase 1 interventional study of AdV-tk and valacyclovir in Malignant Glioma and Recurrent Ependymoma, sponsored by Candel Therapeutics, Inc.. Completed at 2 sites in United States. Open to participants aged 3 Years to 21 Years. Per ClinicalTrials.gov, last updated 2023-08-25.

Primary conditionEpendymomaRegistry: GliomaReclassifiedWhy we changed it
Registry
Glioma — the first condition term the registry derived for this study.
ClinicalTrials.gg
Ependymoma
Why
  1. The study's listed conditions name Ependymoma, a narrower term within Glioma.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Candel Therapeutics, Inc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
3 Years to 21 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 182 studies in Ependymoma with a site in United States — 16 open to participants now, 42 under way, none of them phase 3. Ependymoma · United States.

Enrollment
125th of 155
8 · median 24
Started
2010
with 13 others
Phase 1
80 of 182
8 open now
Registered
55th of 182
by date

Among the 182 studies in Ependymoma with a site in United States, this one is the 125th largest by enrollment of the 155 interventional ones that give a count, is one of 14 that started in 2010, is one of 80 in phase 1, and was the 55th registered.

Ependymoma

224 studies on the registry are indexed under Ependymoma; 35 are open to participants now.

Browse Ependymoma studies →

Open to participants now

16 of the 182 studies in Ependymoma with a site in United States are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 25 Ependymoma studies recruiting now, 7 (28%) set no upper age limit and 16 (64%) stop at 75 or younger; 19 take children under 18; 1 takes healthy volunteers.

This study: 3 Years to 21 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 182 studies in Ependymoma with a site in United States, or all of them as a file.
02

Study summary

This study will evaluate the administration of AdV-tk followed by valacyclovir in children with malignant glioma, including glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA), as well as recurrent ependymomas in combination with radiation therapy. The primary objective is to determine if this approach is safe and can be effectively delivered without disturbing standard therapy.

Read the detailed description

This is an Open label, Phase I, dose escalation study. Patients will receive an injection of AdV-tk into the tumor or tumor bed during the surgical procedure followed by 14 days of anti-herpetic prodrug, valacyclovir, starting 1-3 days after vector injection. Standard radiotherapy will begin 3-7 days after AdV-tK injection. Standard chemotherapy may begin after completion of valacyclovir at the discretion of the treating physician and family. Two dose levels of AdV-tk will be evaluated with a fixed dose of valacyclovir.

03

Conditions studied

  • Malignant Glioma
  • Recurrent Ependymoma

Browse trials for

Keywords

  • Malignant glioma
  • Glioblastoma multiforme
  • Anaplastic astrocytoma
  • Recurrent ependymoma
  • Gene therapy
  • Immunotherapy
04

In context

Ependymoma Reclassified

224 studies on the registry are indexed under Ependymoma; 35 are open to participants now.

This study's enrollment of 8 is below the median of 28 across 174 interventional studies indexed under Ependymoma.

Browse Ependymoma studies →

Lead sponsor

Candel Therapeutics, Inc. is the lead sponsor of 13 studies on the registry; 2 are open to participants now.

Compared within Ependymoma, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Glioma. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
3 Years to 21 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must be 3 years of age or older
  • Patients must be planning to undergo standard of care treatment with surgery and radiation therapy.
  • Patients must have malignant glioma or recurrent ependymoma
  • Tumor must be accessible for injection and must not be located in the brainstem or deep midbrain
  • Performance Score: ≥60% if >10y/o, Lansky ≥60 if ≤10y/o
  • Bone Marrow Function: Patients must have adequate bone marrow function defined as a peripheral ≥ 1000/µl, count ≥ 100,000/µl (transfusion independent) and ≥ 8.0 gm/dL
  • Renal Function: Patients must have serum creatinine ≤ 1.5 times upper limit of institutional normal for age and/or ≥ 70 mL/min/1.73 m2.
  • Hepatic Function: ≤ 1.5 times institutional normal; (ALT) \< 3 times institutional normal
  • Serum electrolyte values (sodium, potassium, magnesium, calcium) must be checked prior to enrollment and abnormalities corrected prior to surgery/AdV-tk injection
  • Patients with seizure disorder may be enrolled if well controlled
  • Signed according to institutional guidelines must be obtained

Exclusion criteria

Exclusion Criteria:

  • Prior or ongoing liver disease including known cirrhosis, or C infection but not to exclude patients with a distant history of resolved hepatitis A infection
  • Patients on drugs (with exception of )
  • Known history of or underlying immunodeficiency
  • Patients with acute infections (viral, bacterial or fungal infections requiring therapy)
  • Pregnant or breast-feeding patients. Female patients of childbearing age must have negative serum or urine pregnancy test within 1 week of beginning therapy
  • Other serious co-morbid illness or compromised organ function
  • No other anti-tumor agents within 30 days prior to study entry or during active participation in the study (defined as from study entry until tumor progression)
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    AdV-tk

    AdV-tk + valacyclovir in combination with standard of care radiation

    Biological: AdV-tk · Drug: valacyclovir · Radiation: Radiation

Interventions

  • BiologicalAdV-tk
  • Also known as: Prodrug

  • RadiationRadiation

    Also known as: Radiation therapy

07

What researchers measure

Primary outcomes

  1. Incidence of treatment emergent adverse events

    Time frame: 2 months

Secondary outcomes

  1. Overall survival

    Time frame: 5 years

  2. Progression-free survival

    Time frame: 5 years

  3. Objective tumor response

    Time frame: 5 years

08

Study locations

2 sites
  • Ann & Robert H. Lurie Children's Hospital of Chicago (Formerly Children's Memorial Hospital)
    Chicago, Illinois 60611, United States
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02115, United States
09

References and documents

Publications

  • Kieran MW, Goumnerova L, Manley P, Chi SN, Marcus KJ, Manzanera AG, Polanco MLS, Guzik BW, Aguilar-Cordova E, Diaz-Montero CM, DiPatri AJ, Tomita T, Lulla R, Greenspan L, Aguilar LK, Goldman S. Phase I study of gene-mediated cytotoxic immunotherapy with AdV-tk as adjuvant to surgery and radiation for pediatric malignant glioma and recurrent ependymoma. Neuro Oncol. 2019 Mar 18;21(4):537-546. doi: 10.1093/neuonc/noy202. PubMed 30883662 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2010 to primary completion in Dec 2015, 62 months.

Of 42 phase 1 interventional studies under Ependymoma, half reached primary completion within 62 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 92. This study's 62 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2008
First posted
Mar 12, 2008
StartActual
Oct 2010
Primary completionActual
Dec 2015
CompletionActual
Jun 2021
Last update
Aug 25, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 25, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00634231
Lead sponsor
Candel Therapeutics, Inc.
Responsible party
Sponsor
First posted
Mar 12, 2008
Start date
Oct 2010
Primary completion
Dec 2015
Completion
Jun 2021
Last update
Aug 25, 2023

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aglatimagene besadenovec

Start the discussion